EMA Probe Into Suicide Risk With Liraglutide & Semaglutide Extended To Other GLP-1 Receptor Agonists

So far authorities have retrieved and are analyzing about 150 reports of possible cases of self-injury and suicidal thoughts, the European Medicines Agency said today.

drug label
Suicidal behaviour is not listed as a side effect in the EU product information for any GLP-1 receptor agonists • Source: Shutterstock

An investigation that the European Medicines Agency started this month into the risk of suicidal and self-harm thoughts when taking Novo Nordisk’s widely-used drugs for weight loss and type 2 diabetes – Saxenda (liraglutide), Wegovy (semaglutide) and Ozempic (semaglutide) – has been extended to include other GLP-1 receptor agonists.

Eli Lilly’s Trulicity (dulaglutide), AstraZeneca’s Byetta (exenatide) and Sanofi’s Lyxumia (lixisenatide) will now also be included in...

More from Europe

UK HRA Working On ‘Trusted’ Path Forward To Support Simplified Informed Consent

 
• By 

The Health Research Authority is working on a streamlined model for informed consent that maintains people’s trust.

EU Ups Ante On Stockpiling For Crises

 

The European Commission has published two new strategies on stockpiling that will improve the availability of critical medicines in times of crisis and reduce the EU’s dependance on suppliers outside the bloc.

‘Seize the Moment:’ European Drug Regulators Called To Act On Changes In US

 

European regulators must work hard to maintain and build vital but fragile trust in science and processes, said speakers at an event celebrating the European Medicines 30th anniversary.

EMA’s PRIME Scheme Explored: Growing Designations - But Are Accelerated Assessments Slipping?

 

While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.

More from Geography

EU Ups Ante On Stockpiling For Crises

 

The European Commission has published two new strategies on stockpiling that will improve the availability of critical medicines in times of crisis and reduce the EU’s dependance on suppliers outside the bloc.

‘Seize the Moment:’ European Drug Regulators Called To Act On Changes In US

 

European regulators must work hard to maintain and build vital but fragile trust in science and processes, said speakers at an event celebrating the European Medicines 30th anniversary.

US FDA To Advisory Committee Industry Reps: Don’t Talk Too Much

 
• By 

Nonvoting industry representative’s presence at Pediatric Advisory Committee meeting was required by statute, the agency said, a de facto acknowledgement that an April directive precluding industry reps from sitting on advisory committees has had little practical effect.